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Research Group, Olten, SwitzerlandBACKGROUND & AIMS: Swallowed topical-acting corticoste-
roids are recommended as ﬁrst-line therapy for eosinophilic
esophagitis (EoE). Asthma medications not optimized for
esophageal delivery are sometimes effective, although given off-
label. We performed a randomized, placebo-controlled trial to
assess the effectiveness and tolerability of a budesonide oro-
dispersible tablet (BOT), which allows the drug to be delivered
to the esophagus in adults with active EoE. METHODS: We
performed a double-blind, parallel study of 88 adults withactive EoE in Europe. Patients were randomly assigned to
groups that received BOT (1 mg twice daily; n ¼ 59) or placebo
(n ¼ 29) for 6 weeks. The primary end point was complete
remission, based on clinical and histologic factors, including
dysphagia and odynophagia severity 2 on a scale of 0–10 on
each of the 7 days before the end of the double-blind phase and
a peak eosinophil count <5 eosinophils/high power ﬁeld. Pa-
tients who did not achieve complete remission at the end of the
6-week double-blind phase were offered 6 weeks of open-label
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Eosinophilic Esophagitis (EoE) is a newly identiﬁed
disease that is rapidly rising in frequency and is now the
second most common disease in the esophagus. Until
now there has been no licenced therapy; treatment
using drugs adapted from other conditions has been
limited and not standardized.
NEW FINDINGS
A newly created, speciﬁc formulation, of topical steroid
was shown in a randomized, placebo controlled, double
blind clinical trial, to resolve both the symptoms and the
underlying inﬂammation in EoE in most patients.
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ATtreatment with BOT (1 mg twice daily). RESULTS: At 6 weeks,
58% of patients given BOT were in complete remission
compared with no patients given placebo (P < .0001). The
secondary end point of histologic remission was achieved
by 93% of patients given BOT vs no patients given placebo
(P < .0001). After 12 weeks, 85% of patients had achieved
remission. Six-week and 12-week BOT administration were
safe and well tolerated; 5% of patients who received BOT
developed symptomatic, mild candida, which was easily
treated with an oral antifungal agent. CONCLUSIONS: In a
randomized trial of adults with active EoE, we found that
budesonide oral tablets were signiﬁcantly more effective
than placebo in inducing clinical and histologic remission.
Eudra-CT number 2014-001485-99; ClinicalTrials.gov ID
NCT02434029.LIMITATIONS
Patients selected for this study were all PPI-resistant.
Long-term outcomes of this therapy need to be
assessed and maintenance regimes, doses and duration
need to be identiﬁed.
IMPACT
This study demonstrates the effectiveness of a newKeywords: Phase 3 Trial; Immune Response; Esophagus;
Patient-Reported Outcomes.
osinophilic esophagitis (EoE) is a chronic, immune-therapy that is speciﬁcally licenced for EoE. The majority
of patients are likely to respond fully and it provides a
licensed standard to which other therapies may be
compared.
* Authors share co-ﬁrst authorship.
Abbreviations used in this paper: BOT, budesonide orodispersible tablet;
DB, double-blind; EEsAI-PRO, Eosinophilic Esophagitis Activity Index–
Patient Reported Outcome; EoE, eosinophilic esophagitis; EoE-QoL-A,
Eosinophilic Esophagitis Quality of Life Scale for Adults; eos/hpf, eosin-
ophils per high power ﬁeld; EoT, end of treatment; EREFS, Endoscopic
Reference Score; HRQoL, health-related quality of life; NRS, numerical
rating scale; OLI, open-label induction; PatGA, Patient’s Global Assess-
ment; PGA, Physician’s Global Assessment; PP, per-protocol; PPI, proton
pump inhibitor; SHS, Short Health Scale; STC, swallowed topical-acting
corticosteroid.
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https://doi.org/10.1053/j.gastro.2019.03.025Emediated, esophageal-restricted disease character-
ized clinically by symptoms related to esophageal
dysfunction and histologically by an eosinophil-
predominant inﬂammation.1 A dramatic increase in inci-
dence and prevalence of EoE has been documented over the
last 2 decades,2 especially in Western countries.3,4 EoE is
currently the most common cause of dysphagia and bolus
impaction,5 and the second leading cause of chronic
esophagitis after gastroesophageal reﬂux disease.6
Predominant symptoms of EoE in adult patients are
chronic dysphagia, food impaction, and chest pain.1 EoE is a
chronic-progressive disease and, if left untreated, is usually
associated with persistence of symptoms and inﬂamma-
tion.7 Furthermore, it is well established that the ongoing
eosinophilic inﬂammation leads to esophageal remodeling,
resulting in ﬁbrosis with possible stricture formation and
functional damage.8,9 Consequently, EoE has a substantial
negative impact on the health-related quality of life
(HRQoL) of patients and their families by causing emotional
distress and restricting social activities.10 There is, there-
fore, a clear indication to treat patients suffering from active
EoE.
Today, swallowed topical-acting corticosteroids (STCs)
are an established ﬁrst-line pharmacologic treatment for
patients with EoE.1 Proton pump inhibitors (PPIs)11 and
dietary modiﬁcations12 are alternatives. From the ﬁrst
positive attempt to treat EoE with STCs, drugs that were
originally developed for airway administration in patients
with asthma,13 multiple trials have conﬁrmed the efﬁcacy of
these compounds in improving symptoms as well as
inﬂammation in patients with EoE.14 Fluticasone or bude-
sonide have shown comparable potencies, but the vehicle
depositing the compound on the esophageal surface seems
to be critical.15 However, variability regarding inclusion
criteria, daily dosages, length of treatment (from 2 to
12 weeks), delivery systems, and the deﬁnition of histologic
remission (from <1 to <20 eosinophils per high power ﬁeld
[eos/hpf]) hampers comparative analyses among thesestudies. In contrast to histologic remission, several trials
could not demonstrate a clear superiority of STCs over
placebo in symptom improvement.16–18
A previous phase 2 trial with a new budesonide oro-
dispersible tablet formulation (BOT, originally deﬁned as an
“effervescent tablet for orodispersible use [BET]”18) in adult
patients with active EoE demonstrated high effectiveness
and safety for short-term treatment, achieving up to 100%
histologic remission rate. Doses of 1 mg or 2 mg BOT twice
daily were equally effective, with 100% and 94.7% remis-
sion rates, respectively.18 The purpose of this multicenter
trial was to evaluate efﬁcacy and safety of this BOT
formulation and to assess the superiority of BOT 1 mg twice
daily over placebo for inducing symptomatic and histologic
remission in adults with active EoE.
76 Lucendo et al Gastroenterology Vol. 157, No. 1
CLINICAL
ATMethods
Study Design and Conduct
This was a randomized, double-blind (DB), placebo-
controlled, parallel group, phase 3 study comparing the efﬁ-
cacy and tolerability of 6 weeks of treatment with budesonide
(BOT 1 mg twice daily) vs placebo in adult patients with active
EoE (see Supplementary Figure 1). Patients not achieving
clinico-histologic remission at the end of the 6-week DB phase,
or who dropped out after at least 4 weeks of DB treatment due
to lack of efﬁcacy, were offered an additional 6 weeks of open-
label induction (OLI) treatment with BOT 1 mg twice daily.
Patients achieving clinico-histologic remission either at end of
treatment (EoT) of DB or OLI phase could enter the mainte-
nance of remission study EOS-2 (EudraCT number
2014-001485-99). The study was conducted at 26 centers in
6 countries from November 2015 to October 2016 (see
Supplementary Material).
The study protocol (see Supplementary Material) was
approved by the national ethics committees in all participating
countries and registered at www.clinicaltrialsregister.eu
(EudraCT 2014-001485-99) and at www.ClinicalTrials.gov
(NCT02434029). All patients provided written informed con-
sent. The study was conducted in accordance with the protocol,
Good Clinical Practice, and within the provisions of the Decla-
ration of Helsinki. The ﬁrst draft of the manuscript was written
by the ﬁrst author; all authors had access to the study data and
reviewed and approved the ﬁnal manuscript.Patients
Key inclusion criteria were the following: patients aged 18–
75 years with clinico-histologic active EoE and being refractory
to treatment with a PPI used at least standard dosages (eg,
omeprazole 20 mg/d, pantoprazole 40 mg/d, esomeprazole 40
mg/d, lansoprazole 30 mg/d, or rabeprazole 20 mg/d) for a 4-
week period.19 Patients had to have a severity of 4 points on a
0–10 numerical rating scale (NRS) for either dysphagia or
odynophagia for 1 day in the week before randomization.
Additionally, Patient’s Global Assessment (PatGA) of EoE ac-
tivity was to be 4 points on a 0–10 NRS. Histologic activity
with peak eos 65/mm2 hpf in at least 1 hpf (corresponding to
20 eos/hpf), as measured in a total of 6 hpfs derived from 6
biopsies, 2 each from the proximal, mid, and distal segments of
the esophagus.
Key exclusion criteria were the following: clinical and
endoscopic suspicion for gastroesophageal reﬂux disease (at
least Los Angeles Classiﬁcation of Esophagitis Grade A); acha-
lasia or scleroderma; evidence of causes other than EoE for
esophageal eosinophilia; pathologic eosinophilic inﬁltration in
gastric and duodenal biopsies; history of esophageal surgery at
any time or of esophageal dilation procedures within the last 8
weeks before screening; any relevant systemic disease; sys-
temic glucocorticosteroids, immunosuppressants, biologic
drugs within 4 weeks before screening, or topical glucocorti-
costeroids within 2 weeks before screening; and onset of
dietary restrictions within 4 weeks before screening.Randomization and Interventions
At baseline, eligible patients were centrally randomized in a
2:1 ratio (verum to placebo) using an Interactive Web ResponseSystem and a computer-generated list of sequentially random
numbers with randomly permuted block size of 6. Allocation
concealment was ensured as patients, investigators and their
study team, the sponsor, monitoring staff, central laboratory,
and central pathologist, were all kept blinded to the randomi-
zation sequence, the block size, and patient’s treatment, until all
patients had completed the study and the database was clean
and locked. No individual unblinding was needed or performed.
At baseline and at each of the 2-weekly interim visits, pa-
tients received study medication for the next period. BOT and
corresponding placebo were identical in physical appearance
and were administered twice daily. The orodispersible tablet
was placed on the tip of the tongue and pressed gently against
the hard palate until it had completely disintegrated by contact
with saliva, the production of which was stimulated by the
slight effervescence of the study medication, which uniquely
differentiates against conventional orodispersible tablet for-
mulations. The components dissolved in saliva were then to be
swallowed (approximately 5–10 swallows within a few
minutes). Patients were instructed to avoid eating, drinking, or
oral hygiene procedures for 30 minutes after study drug
administration. Compliance was assessed by pill count. The use
of other concomitant anti-inﬂammatory drugs (ie, systemic or
topical glucocorticosteroids immunosuppressants, biologic
drugs) or onset of dietary restrictions was not permitted.
Concomitant PPI treatment was to be kept stable.
Procedures
Post-randomization visits took place every 2 weeks during
the DB and the optional OLI phase, and at the 4-week follow-up
visit if the patient did not switch to the EOS-2 maintenance of
remission study (see Supplementary Figure 1).
Clinical symptoms were assessed daily during the 7 days
before baseline and throughout the study using 0–10 points
NRS with obvious face validity for dysphagia and odynophagia,
respectively. Patients completed, at all visits, the PatGA of EoE
activity (0–10 NRS) and the validated Eosinophilic Esophagitis
Activity Index Patient Reported Outcome (EEsAI-PRO) score
(0–100 points).20 Physician’s Global Assessment (PGA) of EoE
activity (0–10 NRS) was assessed at baseline and EoT. Patients
completed the Eosinophilic Esophagitis Quality of Life Scale for
Adults (EoE-QoL-A) questionnaire, version 2.0, a validated 24-
item scale with a 6-questions addendum for those on elimina-
tion diet therapies, to measure HRQoL for adult patients with
EoE, in which every item is scored from 0 (very good HRQoL) to
4 (very poor HRQoL)21,22 licensed from Northwestern Univer-
sity, Evanston, IL. A modiﬁed Short Health Scale (SHS), a visual
analogue scales questionnaire (range 0–100 with lower values
indicating better quality of life) representing each of 4 health
dimensions: Symptom Burden, Social function, Disease-Related
Worry, and General Well-Being, was completed.23 To be used in
this trial with EoE patients, the SHS was modiﬁed by replacing
the terms with respect to the underlying disease in questions
1–3, that is, bowel with the esophageal.
Upper endoscopy was performed during screening and at
EoT and the worst ﬁndings from the total esophagus were
classiﬁed according to the modiﬁed Endoscopic Reference
Score (EREFS) grading system, summing the scores of the 5
major (edema [0–1], rings [0–3], exudates [0–2], furrows [0–1],
strictures [0–1]) and 1 minor (crêpe paper esophagus [0–1])
features; total score ranged from 0 to 9, with higher score
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global assessment of endoscopic EoE activity was performed
and classiﬁed as none, mild, moderate, or severe.
At each endoscopy, 2 biopsies each from the distal, mid, and
proximal esophagus were obtained and analyzed in a blinded
manner by the central pathologist (MV). In addition, biopsies
from the stomach and duodenum were obtained at screening to
exclude concomitant diseases, such as eosinophilic gastroen-
teritis. Biopsy specimen were ﬁxed in 4% neutral-buffered
formalin and embedded in parafﬁn. On each H&E-stained
esophageal biopsy specimen, all levels were surveyed and the
eosinophils in the most densely inﬁltrated area were counted
(hpf area of 0.345 mm2) and reported as eos/mm2 hpf. The
cutoff level for histologic remission of <16 eos/mm2 hpf was
chosen, as the same microscope was used in the previous trial
by Straumann et al25 and in the recent phase 2 trial with BOT,18
and which corresponds to <5 eos/hpf as reported by Strau-
mann et al.
In patients with suspected local fungal infection (ie, based
on clinical symptoms, endoscopic appearance, or even from
suspicious H&E-stained histologic slides), sensitive Grocott
silver staining was performed on esophageal biopsy specimen
for ﬁnal conﬁrmation.Safety and Tolerability
Physical examinations were performed during screening
and at EoT visits. Vital signs, concomitant medications, and
adverse events were recorded, and general laboratory tests and
urinalysis were performed. Serum morning cortisol (8:00–9:00
AM) levels were measured at Baseline and EoT visits. Tolera-
bility was classiﬁed independently by the patient and the
investigator at the EoT.Study End Points
The primary efﬁcacy end point was the rate of patients with
clinico-histologic remission at week 6, that is, achieving both,
histologic remission at EoT (peak eosinophil count <16 eos/
mm2 hpf) and clinical remission (symptoms severity of 2
points on each 0–10 NRS for dysphagia and odynophagia,
respectively on each day in the week before EoT). Occurrence
of food impaction, needing for endoscopic intervention or
dilation, or prematurely withdrawal was assessed as treatment
failure.
Secondary a priori–ordered end points, which could be
tested in a conﬁrmatory manner, included histologic remission,
change in peak eosinophil count, resolution of symptoms on
each day in the week before the EoT, and rate of clinical
remission deﬁned as EEsAI-PRO 20 at EoT. A full list of all
clinical, endoscopic, histologic, and HRQoL end points used is
shown in Supplementary Table 1.Statistical Analyses
Assuming remission rates of 10% and 50% under placebo
and BOT, respectively, simulations with ADDPLAN 6 (licensed
by ADDPLAN, Inc, an ICON Clinical Research, LLC company)
showed that a total of 81 full analysis set (FAS) patients (2:1
randomization) were needed to detect this difference of 40% in
true remission rates using Fisher’s exact test (1-sided a ¼ .025)
with a statistical power of at least 90%. This sample size wasincreased to account for 10% of randomized patients who did
not take at least 1 dose of the study drug.
For the primary end point, proportions of patients with
clinico-histologic remission at week 6 with last observation
carried forward were compared between treatment groups
using 1-sided Fisher’s exact test. Efﬁcacy signiﬁcance testing
continued in hierarchical fashion for the a priori–ordered key
secondary end points. Once a 1-sided non-signiﬁcant P value
(> .025) occurred, subsequent signiﬁcance tests were consid-
ered exploratory. Dichotomous key secondary end points were
analyzed using Fisher’s exact test. Change in the peak eos/mm2
hpf was analyzed by ﬁtting a linear least squares model with
treatment effect and baseline value as covariate.
Exploratory comparisons of further end points between
treatment groups or between baseline and end of treatment
were performed using 2-sided t tests or Wilcoxon rank sum
tests, as appropriate, in case of continuous data. Two-sided
Fisher’s exact test was applied to dichotomous data. Descrip-
tive statistics were used to summarize data, including in-
cidences of adverse events.
Analyses were performed using SAS, version 9.3 (SAS
Institute, Cary, NC) and ADDPLAN, version 6.1.1 and according
to the intention-to-treat principle. Missing data at week 6 were
replaced using the last observation carried forward method.Results
Patient Flow and Baseline Characteristics
In total, 126 patients were screened, 88 met inclusion
criteria and were randomized and treated. In total, 82 pa-
tients completed the DB phase (92.0%), but all 88 patients
were evaluable for the primary analysis (Supplementary
Figure 2).
Both treatment groups had similar baseline character-
istics (Table 1), being typical for an adult patient population
with EoE. Both study arms had a similar peak eosinophil
count and moderate to severe esophageal symptom scores
as assessed by NRS for dysphagia, odynophagia; NRS for
PatGA and PGA, EEsAI-PRO, and dysphagia-free days.
HRQoL, as measured by modiﬁed SHS and EoE-QoL-A
scores, was moderately impaired in both treatment groups
at baseline (Table 1).
Clinical Efﬁcacy
The primary end point of clinico-histologic remission at
week 6 was achieved in 34 of 59 (57.6%) patients receiving
budesonide, but in none of the 29 (0%) patients receiving
placebo (P < .0001) (Figure 1). This ﬁnding was extremely
robust, as the per-protocol analysis (data not shown) as well
as further protocol speciﬁed subgroup analyses were all in
complete alignment. For example, the rates of clinico-
histologic remission were not signiﬁcantly inﬂuenced by
the peak eosinophil count at baseline conditions, presence
or absence of concomitant allergic diseases, blood eosino-
phil density, concomitant PPI use, or disease duration
(Supplementary Table 2).
A further 6-week OLI therapy with BOT 1 mg twice daily
was offered to clinical or histological non-responders at EoT
of DB phase and was chosen by 23 patients from the BOT
Table 1.Demographic, Anamnestic, and Baseline Disease Characteristics of Study Patients
Characteristic
BOT 1 mg bid
(n ¼ 59)
Placebo
(n ¼ 29)
Male, n (%) 48 (81) 25 (86)
White, n (%) 59 (100) 29 (100)
Age, y, mean (SD) 37 (11.5) 37 (9.2)
Body mass index , kg/m2, mean (SD) 24.4 (2.9) 25.6 (4.1)
Time since ﬁrst EoE symptoms, mo, mean (SD) 134 (104.6) 139 (98.8)
Time since EoE diagnosis, mo, mean (SD) 49 (44.3) 58 (49.3)
History of allergic disease, n (%) 47 (80) 23 (79)
History of having experienced, n (%)
Dysphagia 58 (98) 29 (100)
Odynophagia 35 (59) 14 (48)
Food impaction 56 (95) 26 (90)
Frequency of dysphagia in the last week, n (%)
Never 2 (3) 0 (0)
1–3/wk 21 (36) 12 (41)
4–6/wk 10 (17) 2 (7)
Daily 24 (41) 13 (45)
Missing 2 (3) 2 (7)
Daily dysphagia (NRS 0–10) in the last week, mean (SD) 5.8 (2.0) 5.9 (1.7)
Weekly sum of daily dysphagia NRS (0–70), mean (95% CI) 35 (30–39) 36 (32–41)
Daily odynophagia (NRS 0–10) in the last week, mean (SD) 3.5 (2.8) 3.4 (3.2)
Weekly sum of daily odynophagia NRS (0–70), mean (95% CI) 27 (23–32) 26 (19–32)
Total weekly EEsAI-PRO (0–100), mean (SD) 54 (16) 55 (16)
Modiﬁed SHS (VAS 0–100), mean (SD)
Symptom burden 58 (24) 55 (18)
Social function 55 (29) 46 (24)
Disease-related worry 57 (26) 52 (27)
General well-being 40 (23) 35 (29)
EoE-QoL-A questionnaire (0–4), mean (SD)
Overall (24 items, weighted average) 2.23 (0.800) 2.30 (0.763)
Eating/diet impact (10 items, weighted average) 2.19 (1.023) 2.30 (0.848)
PatGA of EoE activity (NRS 0–10), mean (SD) 5.9 (1.5) 6.0 (1.5)
PGA of EoE activity (NRS 0–10), mean (SD) 6.1 (1.3) 6.2 (1.3)
Overall peak eos/mm2 hpf, median (range) 205 (56–611) 197 (99–620)
Peak eos/mm2 hpf by esophageal location, median (range)
Proximal 83 (0–568) 153 (0–603)
Mid 142 (0–504) 136 (0–620)
Distal 176 (0–611) 139 (0–527)
Localization of inﬂammation, n (%)
Proximal 47 (80) 25 (86)
Mid 52 (88) 26 (90)
Distal 56 (95) 28 (97)
No. of inﬂamed segments, n (%)
1 segment 6 (10) 2 (7)
2 segments 10 (17) 4 (14)
3 segments 43 (73) 23 (79)
Total modiﬁed EREFS score (0–9), mean (SD) 3.8 (1.5) 4.6 (1.3)
Subscore inﬂammatory signs (0–4), mean (SD) 2.7 (1.0) 3.0 (1.0)
Subscore ﬁbrotic signs (0–4), mean (SD) 1.0 (1.0) 1.4 (0.9)
Endoscopic ﬁndings, n (%)
Normal 0 (0) 0 (0)
Exudates 47 (80) 23 (79)
Rings 33 (56) 24 (83)
Edema 44 (75) 24 (83)
Furrows 50 (85) 29 (100)
Strictures 9 (15) 4 (14)
Crêpe paper 10 (17) 3 (10)
Endoscopist’s assessment of EoE activity, n (%)
None 1 (2) 0 (0)
Mild 9 (15) 3 (10)
Moderate 30 (51) 17 (59)
Severe 19 (32) 9 (31)
78 Lucendo et al Gastroenterology Vol. 157, No. 1
CLINICAL
AT
Table 1.Continued
Characteristic
BOT 1 mg bid
(n ¼ 59)
Placebo
(n ¼ 29)
Blood, eos/mm3, mean (SD) 427 (255) 455 (256)
Failed PPI trial (either previously or during the screening
phase), n (%)
56 (100) 29 (100)
Concomitant treatment with PPI, n (%) 7 (12) 3 (10)
EoE medications/interventions used in the patient’s history,
n (%)a
PPI 32 (54) 13(45)
Topical budesonide 12 (20) 3 (10)
Topical ﬂuticasone 25 (42) 14 (48)
Systemic steroids 3 (5) 0 (0)
Other (Montelucast, Singulair) 4 (7) 0 (0)
Endoscopic dilation 9 (15) 5 (17)
Elemental diet 0 (0) 0 (0)
Directed elimination diet (based on allergy test) 4 (7) 4 (14)
Non-directed elimination diet 24 (41) 10 (35)
bid, twice daily; CI, conﬁdence interval; n, valid number; PPI, proton pump inhibitor.
aPreviously reported efﬁcacy of drug interventions in the patient’s history is presented in Supplementary Table 11.
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groups (placebo/BOT) (Supplementary Table 3). As
achievement of clinical remission (Figure 2A–C) takes longer
than achievement of histologic remission under BOT 1 mg
twice daily, the majority of BOT/BOT patients were
already in histologic remission at EoT of DB phase (93.2%)
(Table 2), but beneﬁted clinically from a prolongedFigure 1. Primary study end point in EoE patients treated with
BOT or placebo in the 6-week DB phase. Clinico-histologic
remission was deﬁned as achieving both histologic remis-
sion (peak eosinophil count <16 eos/mm2 hpf; equivalent to
<5 eos/hpf) at week 6 (LOCF) and clinical remission (symp-
toms severity of 2 points on 0–10 NRS for dysphagia and a
severity of 2 points on 0–10 NRS for odynophagia on each
day in the week before week 6 (LOCF) (1-sided Fisher’s exact
test). Patients who experienced food impaction needing
endoscopic intervention, needed a dilation during the study,
or withdrew prematurely were assessed as treatment failure.
BID, twice daily; CI, conﬁdence interval; LOCF, last obser-
vation carried forward.treatment with BOT 1 mg twice daily (Supplementary
Figure 3). The overall cumulative clinico-histologic remis-
sion rate after up to 12 weeks of treatment with BOT 1 mg
twice daily was therefore 84.7% (50 of 59 patients),
providing evidence that a prolonged treatment for up to 12
weeks is beneﬁcial to bring more patients into clinico-
histologic remission.
All 4 a priori–ordered major secondary efﬁcacy end
points proved superiority of BOT 1 mg twice daily vs pla-
cebo in a conﬁrmatory manner (Table 2). Clinical remission,
as deﬁned in the primary composite end point, was achieved
in 59.3% vs 13.8% (P < .0001) in the BOT and placebo
group, respectively (Table 2), and was in line with alterna-
tive deﬁnitions of clinical remission (EEsAI-PRO 20:
50.8% vs 6.9%; P < .0001); PatGA 2: 64.4% vs 24.1%;
P ¼ .0006; see also Figure 3A–C for course of clinical
remission/response).
Histologic remission after 6 weeks of DB phase, irre-
spective of symptoms, was achieved in 93.2% and 0% in the
BOT 1 mg twice daily and placebo groups, respectively
(P < .0001). All but 3 patients in the BOT 1 mg twice daily
group showed a dramatic decrease from baseline in peak
eosinophil count, independently of the eosinophil load at
baseline (Figure 3A), demonstrating that BOT 1 mg twice
daily was able to induce remission, even in severely
inﬂamed cases. Histologic remission in the BOT 1 mg twice
daily group was independently achieved in all esophageal
segments (Figure 3B), and irrespectively from the extent of
the inﬂamed area, as even patients with a pan-esophageal
inﬂammation where all 3 segments of the esophagus were
affected, achieved histologic remission rates of 95.3%
(Figure 3C) (P < .0001 for each comparison). Changes in
peak eosinophil count (total and by esophageal segment)
are provided in Supplementary Table 4.
In addition, the mean decrease in PatGA of EoE activity
in the BOT 1 mg twice daily group (–3.6 points) was
Figure 2. Course of clinical improvement and remission in
EoE patients treated with BOT or placebo in the DB phase. (A)
Course of achieved clinical remission deﬁned as EEsAI-PRO
score of 20 points (1-sided Fisher’s exact test). (B) Course
of achieved resolution of dysphagia deﬁned as 2 points on a
0–10 point NRS for dysphagia on each day in the week before
a visit (2-sided Fisher’s exact test). (C) Course of the number
of days in the week before a visit, with none or only minimal
dysphagia (ie, dysphagia 2 points on a 0 to 10-point NRS
for dysphagia (2-sided Wilcoxon rank sum test). BID, twice
daily; BOT, budesonide oro-dispersible tablets; CI, conﬁ-
dence interval; LOCF, last observation carried forward.
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.0073). The PGA of EoE activity mirrored the ﬁndings
observed with the PatGA, with a signiﬁcantly higher
decrease under BOT 1 mg twice daily (–3.8 points)
compared to placebo (–0.8 points; P < .0001) (Table 2).
Mean reductions from baseline to EoT in modiﬁed
EREFS total score and its inﬂammatory and ﬁbrotic sub-
scores were in the BOT 1 mg twice daily and placebo
groups, respectively, –2.6 vs –0.1 (P < .0001), –2.1 vs 0.0
(P < .001), and –0.4 vs 0.0 (P ¼ .2204). However, the
change of –0.4 points in the ﬁbrotic subscore under BOT 1mg twice daily treatment was relevant and also signiﬁcant
(P ¼ .0006; Table 2). Changes in each of the EREFS
component are provided in Supplementary Table 5. A
complete normalization of the esophageal appearance was
reported in 61% vs 0% of the patients in the BOT 1 mg
twice daily and placebo group, respectively (P < .0001)
(Table 2).
QoL measured with the generic modiﬁed SHS instrument
showed, for all 4 dimensions, a numerically higher and
signiﬁcant improvement (absolute change) in mean scores
from baseline to week 6 for the BOT 1 mg twice daily group,
but only a signiﬁcant change from baseline to EoT for
Symptom Burden and Social Function domain in the placebo
group (Figure 4A). The comparison of absolute changes
between the treatment groups revealed superiority of BOT 1
mg twice daily over placebo in the domains of Social
Function and Disease-Related Worry, as the 95% conﬁdence
interval of the group differences (BOT 1 mg twice daily–
placebo) excluded 0 (Figure 4B).
With the disease-speciﬁc EoE-QoL-A questionnaire and
its subscores, the improvements from baseline to EoT in
HRQoL were all signiﬁcant for the BOT 1 mg twice daily
group, but only signiﬁcant for the 30-item, 24-item, social
impact, emotional impact, and swallowing anxiety score in
the placebo group (Supplementary Table 6). The intra-group
comparison of the mean changes from baseline to EoT were
signiﬁcant for BOT 1 mg twice daily vs placebo for sub-
scores “eating/diet impact 10 items”: 0.7 vs 0.2, P ¼ .0030
and for “eating/diet impact 4 items”: 0.7 vs 0.2, P ¼ .0082
(Supplementary Table 6). Quality of life data from the OLI
phase are provided in Supplementary Table 7.Safety
Overall, BOT 1 mg twice daily was well tolerated in this
study. No serious adverse event was reported. However,
food impaction requiring endoscopic emergency interven-
tion occurred in 1 patient receiving placebo. No important
differences were observed among the study groups in the
most commonly reported adverse events, despite that a
higher proportion of patients with suspected treatment-
emergent adverse drug reactions at the end of DB phase
were assigned to the budesonide group (27 of 59) than to
the placebo group (1 of 29) (Table 3). Suspected local fungal
infections were more common with budesonide than with
placebo: suspected candidiasis in endoscopy carried out per
protocol at EoT visit was conﬁrmed histologically in only 10
of 59 (16.9%) patients. Finally, and clinically most impor-
tant, only 3 (5.1%) of these patients presented with clinical
symptoms (2 patients with esophageal symptoms and 1
with oral and esophageal symptoms), all of mild intensity,
with no impact on daily life activities, and which recovered
after medical treatment. No candidiasis appeared in patients
assigned to placebo.
There were no laboratory-related treatment-emergent
adverse events. Additionally, there were no signiﬁcant dif-
ferences between treatment groups in cortisol levels at the
EoT assessment (Supplementary Table 8). A decrease in
serum morning cortisol from normal at screening to a value
Table 2.A Priori–Ordered Major Secondary and Further Exploratory Efﬁcacy End Points of Eosinophilic Esophagitis Patients
Treated With Budesonide Orodispersible Tablet 1 mg Twice Daily or Placebo in the Double-Blind Phase
End point
BOT 1 mg bid
(n ¼ 59)
Placebo
(n ¼ 29)
P
value
A priori–ordered major secondary efﬁcacy end points (DB phase)
1. Rate of patients with histologic remission (ie, peak
eos <16 /mm2 hpf; equivalent to <5 eos/hpf) at wk 6, n (%)
55 (93.2) 0 (0) <.0001a
2. Change in the peak eos/mm2 hpf from baseline to wk 6,
mean (SD)
–226 (150.4) –4 (135.6) <.0001b
3. Rate of patients with clinical remission (as deﬁned in the primary
end point) at wk 6, n (%)
35 (59.3) 4 (13.8) <.0001a
4. Rate of patients in clinical remission (total weekly
EEsAI-PRO 20) at wk 6, n (%)
30 (50.8) 2 (6.9) <.0001a
Further exploratory efﬁcacy end points (DB phase)
Clinic
Weekly sum of daily 0–10 NRS dysphagia (range, 0–70) ‘
Baseline, mean (SD) 34.6 (16.1) 36.4 (12.4) —
EoT,c mean (SD) 14.5 (16.4) 24.9 (11.0) —
Change from baseline to wk 6, mean (SD) –20.1 (17.0) –11.4 (11.0) .0230d
PGA of EoE activity (NRS 0–10)
Baseline, mean (SD) 6.1 (1.3) 6.2 (1.3) —
EoT,c mean (SD) 2.3 (2.5) 5.5 (2.1) —
Change from baseline to wk 6, mean (95% CI) –3.8 (–4.4 to –3.2) –0.8 (–1.6 to 0.1) <.0001d
PatGA of EoE activity (NRS 0–10)
Baseline, mean (SD) 5.9 (1.5) 6.0 (1.5) —
EoT,c mean (SD) 2.3 (2.6) 4.1 (2.1) —
Change from baseline to wk 6, mean (95% CI) –3.6 (–4.3 to –2.9) –1.9 (–3.0 to –0.9) .0073d
Rate of patients with overall symptoms resolution deﬁned as
PatGA 2 at EoT,c n (%)
38 (64.4) 7 (24.1) .0006a
Change from baseline to EoTc in blood eosinophil counts,
eos/mm3, mean (95% CI)
–219 (–288 to –150) –28 (–124 to 68) .0016d
Endoscopy
Total modiﬁed EREFS endoscopic score (0–9)
Baseline, mean (SD) 3.8 (1.5) 4.6 (1.3) —
EoT,c mean (SD) 1.2 (1.4) 4.5 (1.6) —
Change from baseline to EoTc mean (95% CI) –2.6 (–3.1 to –2.1) –0.1 (–0.8 to 0.5) <.0001d
P value <.0001e .7358e —
Modiﬁed EREFS inﬂammatory signs subscore (0–4)
Baseline, mean (SD) 2.7 (1.0) 3.0 (1.0) —
EoT,c mean (SD) 0.6 (0.9) 3.0 (1.0) —
Change from baseline to EoTc mean (95% CI) –2.1 (–2.5 to –1.7) 0.0 (–0.4 to 0.3) <.0001f
P value <.0001g .9646g —
Modiﬁed EREFS ﬁbrotic signs subscore (0–4)
Baseline, Mean (SD) 1.0 (1.0) 1.4 (0.9) —
EoT,c Mean (SD) 0.6 (0.7) 1.4 (1.0) —
Change from baseline to EoTc mean (95% CI) –0.4 (–0.6 to –0.2) –0.1 (–0.5 to 0.4) .2204f
P value P ¼ .0006g P ¼ .8074g —
Rate of patients with global assessment of endoscopic EoE
activity of no signs of EoE at EoT,c n (%)
36 (61.0) 0 (0) <.0001a
Histology
Rate of patients with histologic remission (ie, peak eos <48/mm2
hpf; equivalent to <15 eos/hpf) at wk 6, n (%)
56 (94.9) 0 (0) <.0001a
Post-hoc analysis
Rate of patients in deep histologic remission deﬁned as
peak eos/mm2 hpf of 0 in all biopsies at EoT,c n (%)
53 (89.8) 0 (0) <.0001a
bid, twice daily.
aTwo-sided Fisher’s exact test (test between groups).
bOne-sided P value for effect between treatment groups from linear least squares model with treatment group and baseline
value as covariate.
cWeek 6, last observation carried forward.
dTwo-sided t test (test between groups).
eTwo-sided, 1-sample t test (test within group).
fTwo-sided Wilcoxon rank sum test (test between groups).
gTwo-sided Wilcoxon signed rank test (test within group).
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Figure 3. Histologic
changes and remission in
EoE patients treated with
BOT 1 mg bid or placebo in
the DB phase. (A) Individual
pre- and post-treatment
peak eos/mm2 hpf counts
and median group values
with IQR (2-sided Wilcoxon
signed rank test for intra-
group changes); (B) histo-
logic remission stratiﬁed by
the localization of the
affected esophagus
segment (2-sided Fisher’s
exact test), and (C) stratiﬁed
by the extent of the eosino-
philic inﬂammation (either 1,
2, or all 3 segments
involved) at baseline (2-
sided Fisher’s exact test).
BID, twice daily; IQR, inter-
quartile range; LOCF, last
observation carried forward.
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in only 3 (5.1%) patients in the budesonide arm
(Supplementary Table 9). No patient had to prematurely
stop administration of the study medication.
Safety results from the 6-week OLI phase did not reveal
any new safety signal (Supplementary Table 10).Discussion
This is a pivotal phase 3 trial reporting on the efﬁcacy
and safety of a medicinal product to treat active EoE in
adults. In this multicenter trial, budesonide in an orodis-
persible tablet formulation was highly effective and safe in
bringing adult patients with active EoE into clinical and
histologic remission. As EoE is diagnosed by the presence of
symptoms of esophageal dysfunction (mainly dysphagia)
and histologic inﬂammation with >15 eos/hpf, a composite
end point of achieving both clinical and histologicalremission is an appropriate readout. A 6-week treatment
with 1 mg budesonide twice daily was highly superior over
placebo with regard to all predeﬁned primary and second-
ary outcomes.
Nevertheless, assessment of the clinical response in EoE
is a challenge because the leading symptom of solid food
dysphagia depends not only on the activity of the disease,
but also on the eating behavior of the patient. Clinical
remission as deﬁned in the primary composite end point
was highly superior under BOT 1 mg twice daily compared
to placebo in a conﬁrmatory manner. A direct comparison
between other studies with STCs is difﬁcult, as they used
different readouts and cutoffs for deﬁning clinical remission.
However, our NRS for dysphagia was a simple tool with
obvious face validity, and was also conﬁrmed recently to be
responsive to assess dysphagia severity in EoE in clinical
practice.26 The chosen cutoff of 2 was in line with all other
important clinical end points based on different tools
Table 3.Eosinophilic Esophagitis Patients Treated With
Budesonide Orodispersible Tablets or Placebo in the
Double-Blind Phase and Experiencing Treatment-
Related Adverse Events
Variable
BOT 1 mg
bid
(n ¼ 59)
Placebo
(n ¼ 29)
Any TEAE 37 (62.7) 12 (41.1)
Severe TEAE 0 (0) 1 (3.4)
Esophageal food impaction 0 (0) 1 (3.4)
TEAE related to study drug 23 (39.0) 1 (3.4)
Serious AEs 0 (0) 0 (0)
TEAE leading to withdrawal from the study 0 (0) 1 (3.4)
Esophageal food impaction of severe
intensity requiring endoscopic
intervention
0 (0) 1 (3.4)
TEAEs by occurring in 2 patients in any
treatment group
Gastrointestinal disorders 10 (16.9) 3 (10.3)
Gastroesophageal reﬂux disease 3 (5.1) 0 (0)
Nausea 2 (3.4) 0 (0)
Infections and infestations 21 (35.6) 6 (20.7)
Suspected local fungal infection,a
thereof:
14 (23.7) 0 (0)
Histologically conﬁrmedb 10 (16.9) 0 (0)
Histologically conﬁrmedb with
suspected endoscopic signs
8 (13.6) 0 (0)
Histologically conﬁrmedb with
suspected endoscopic signs and
clinical symptoms
3 (5.1) 0 (0)
Nasopharyngitis 2 (3.4) 1 (3.4)
Pharyngitis 1 (1.7) 2 (6.9)
Investigations 5 (8.5) 0 (0)
Blood cortisol decreased 3 (5.1) 0 (0)
Nervous system disorders 5 (8.5) 1 (3.4)
Headache 4 (6.8) 1 (3.4)
Respiratory, thoracic and mediastinal
disorders
2 (3.4) 2 (6.9)
Asthma 0 (0) 2 (6.9)
Vascular disorders 3 (5.1) 0 (0)
Hypertension 2 (3.4) 0 (0)
bid, twice daily; TEAE, treatment-emergent adverse events.
aLocal fungal infection (included suspected cases of candida
infection, esophageal candidiasis, oral candidiasis, and
oropharyngeal candidiasis) was suspected and assessed as
an adverse event if any of the following criteria was fulﬁlled:
suspected clinical symptoms, suspected endoscopic ﬁnd-
ings, suspected histologic assessment in H&E-stained bi-
opsies (even without any endoscopic signs or clinical
symptoms).
bHistologically conﬁrmed by Grocott staining.
Figure 4. Changes in HRQoL by means of the modiﬁed SHS
in EoE patients treated with BOT or placebo in the DB phase.
(A) Mean pre- and post-treatment scores of the 4 dimensions
of the modiﬁed SHS showed a greater improvement in BOT-
treated patients, with lower values indicating better quality of
life. All dimensions improved signiﬁcantly from baseline to
week 6 (LOCF) under BOT, whereas only Symptom Burden
and Social Function improved signiﬁcantly. (B) The 95% CI of
the group differences (BOT 1 mg BID–Placebo) in mean ab-
solute changes, which excluded 0, indicated a superiority of
BOT 1 mg BID over placebo in the dimensions of Social
Function and Disease-Related Worry. All intra- and inter-
group comparisons were performed using 2-sided 1-sample
t test and 2-sided t test, respectively. BID, twice daily; CI,
conﬁdence interval; LOCF, last observation carried forward;
VAS, visual analogue scale.
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remission rates based on cutoffs 2 on a 1–10 scale (PatGA,
PGA) or 20 on a 1–100 scale (EEsAI-PRO).
Recently, Hirano et al27 used a similar PatGA and PGA in
their trial with RPC4046, an anti–interleukin-13 monoclonal
antibody. In that study, the pre–post PatGA in the highest
RPC dose group decreased from 5.4 to 2.5 points and the
PGA from 6.1 to 3.2, which was comparable to our study
with PatGA, which decreased from 5.9 to 2.3 and PGA from
6.1 to 2.3. However, in the study by Hirano et al, approxi-
mately 50% of patients were steroid-refractory, whereas in
our study only 11% of patients showed a previously poor
response to steroids, which might explain the slightly better
improvement in our study.
Histologic improvement of EoE is directly related
to therapy with a higher mucosal contact time, which
highlights the importance of using appropriate drugformulations with optimized esophageal targeting. Our data
conﬁrm the results of the phase 2 trial, which reported a
100% histologic remission rate18 and showed that BOT 1
mg twice daily had similar anti-inﬂammatory effects in the
entire esophagus, independent of severity, localization, or
extent of inﬂammation (Figure 2A–C), indicating optimal
esophageal targeting with BOT 1 mg twice daily.
More patients achieved histologic remission of EoE in
our trial compared to clinical remission. Thus, nearly every
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ATpatient in clinical remission at EoT was also in histologic
remission, but not vice versa. The data underscore the
repeatedly documented imperfect relationship between
esophageal symptoms and the biological activity of EoE.28,29
The potential causes for this might include the presence of
mild esophageal strictures (15% in both arms in the present
study), an esophageal narrow caliber underestimated with
endoscopy,30 a decreased esophageal distensibility,31 or
symptoms unrelated with EoE but due to coexistent
comorbidities. In any case, it highlights the need to consider
both aspects in the evaluation of patients with EoE.
Of note, the histologic remission rate of 93.2% was
strikingly higher than those achieved in all previously per-
formed trials with other budesonide formulations in adult
EoE patients.25,32 In a recent phase 2 trial with a viscous
budesonide suspension with a high volume of 10 mL/
application and doubled daily dose, only 39% of the patients
achieved histologic remission, deﬁned as 6 eos/hpf, after a
12-week course.32 This difference might be explained by the
different pharmaceutical formulations used. Although in a
recent trial, the oral viscous suspension was more effective
than a nebulized steroid preparation,33 which was explained
by a prolonged contact time, the scintigraphy points to the
fact that the majority of the drug ended up in the stomach.
In contrast to a twice-daily single swallow of a relative large
volume of 10 mL viscous suspension, BOT 1 mg twice daily
offered a unique method of delivery. As soon as BOT is put
on the tongue, it stimulates the production of saliva via its
effervescence characteristics for approximately 2–3
minutes—the period during which the BOT completely
dissolves. During this period, budesonide-enriched saliva is
continuously swallowed in small volumes. It can be specu-
lated that the naturally mucus adhesive characteristic of the
saliva then leads to optimal adhesion and prolonged contact
time, such that even with 1 mg twice daily, histologic
remission rates are twice as high as a 2-mg twice daily
dosing with oral viscous suspension in a high volume.
Endoscopically, treatment with BOT 1 mg twice daily
resulted in signiﬁcant changes from baseline to EoT in the
total modiﬁed EREFS, as well as in its inﬂammatory signs
subscore. Surprisingly, a 6-week treatment with BOT 1 mg
twice daily already signiﬁcantly decreased the ﬁbrotic signs
subscore, indicating that prolonged treatment with BOT
might have a substantial impact on re-modeling. Therefore,
long-term data are needed and actually being addressed by
the ongoing EOS-2 maintenance of remission trial (EudraCT
number 2014-001485-99). Comparisons between different
trials are hindered by the fact that either the original EREFS
score or its modiﬁed version were used (as done in our
trial), or that the EREFS score was assessed by separate
segments, whereas we used the worst-case assessment
resulting from the whole esophagus.
Both HRQoL tools (modiﬁed SHS and EoE-QoL-A)
showed a signiﬁcant improvement in HRQoL in all
domains and items under BOT 1 mg twice daily, with
numerically larger improvement compared to placebo. This
was statistically signiﬁcant already after a 6-week short
treatment for the domains of Social Function and Disease-
Related Worry using the modiﬁed SHS and the EoE-QoL-A“eating/diet impact 10 and 4 items (weighted average)”
domains scores.
The main side effect of STCs is local fungal infection. In
this study, we searched systematically for candidiasis, that
is, clinically, endoscopically, and histologically regarding
localization and clinical relevance. In a worst-case scenario,
histologically suspected ﬁndings of local fungal infection
were classiﬁed as adverse events, even without any endo-
scopic signs or clinical symptoms. Therefore, this approach
reﬂects a worst-case scenario, which is uncommon in daily
practice and also not used and reported in other trials. Far
more important are the rates of histologically conﬁrmed
cases of local fungal infections associated with endoscopic
and clinical signs. However, these cases occurred in only 5%
of patients under a 6-week BOT 1 mg twice daily treatment,
without a further increase in patients treated up to 12
weeks.
An additional concern when using topical corticosteroids
is the risk of inducing adrenal axis suppression. The deter-
mination of the morning fasting cortisol levels showed no
difference between the treatment groups, and a clinically
signiﬁcant decrease in serum cortisol levels was reported
for only 3 patients under BOT 1 mg twice daily treatment,
which normalized after the end of treatment.
The main strength of the study lies in its rigorous design
and multicenter conduct: The use of clinico-histologic
remission of EoE as the primary end point, in accordance
with the deﬁnition of EoE, in which clinical manifestations
or pathologic data should not be interpreted in isolation.1,19
Validated instruments were used to evaluate symptoms,
endoscopic features, and changes in HRQoL along the trial,
and adverse events and safety issues were monitored
comprehensively and assessed.
Our study also has some limitations. First, it was not
designed to identify the time of the maximal effect of
budesonide as induction therapy but to demonstrate a sig-
niﬁcant superiority compared to placebo at week 6. Greater
efﬁcacy may be obtained by extending induction treatment
beyond 6 weeks, as most of the trials that assessed efﬁcacy
of topical steroids in EoE already did,16,17,32–35 and also as
the data of patients with a prolonged treatment of up to 12
weeks suggested in our OLI phase. Second, we did not
identify a minimally effective dose regimen because we used
the lower of the 2 doses (ie, 1 mg and 2 mg BOT twice daily),
both of which demonstrated histologic remission in almost
all of the patients who participated in our phase 2 trial.18
Our histologic remission rate does not preclude that an
even lower dose than 1 mg twice daily could still achieve
disease remission in a signiﬁcant proportion of patients
compared to placebo. In contrast, we believe that a higher
dose would not achieve a higher clinico-remission rate.
Third, we excluded, at screening, patients with severe
strictures unable to be passed with a standard gastroscope,
ruling out the possibility that some strictures with a pre-
dominant inﬂammatory component may have responded to
BOT. However, patients with mild strictures were included,
and ﬁbrotic features of the EREFS score overall improved at
EoT. Fourth, symptomatic improvement during OLI phase
could have overestimated the effect of therapy because
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active medication. Finally, concomitant treatment with PPIs
was allowed along the trial, which could have contributed to
the symptomatic improvement at the EoT. However, every
recruited patient has excluded a PPI response, and
dysphagia was longitudinally assessed in every individual
patient along the study period. Only <12% of patients
recruited continued their underlying PPI treatment with
stable dosing.
In conclusion, compared to placebo, BOT 1 mg twice
daily is a highly effective therapy to rapidly induce disease
remission in adult patients with active EoE; an ongoing trial
with the same formulation will provide evidence on its ef-
ﬁcacy to maintain this remission in the long term.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at https://doi.org/10.1053/
j.gastro.2019.03.025.References
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Stefan Schubert, Peter Armerding, Wolf Peter Hofmann, Thomas Liceni Praxis für Innere Medizin und Gastroenterologie, Berlin
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Teresa Rodriguez
Hospital Universitario de la Princesa, Madrid
Constanza Ciriza de los Ríos, Fernando Canga Rodríguez-Valcárcel,
Isabel Castel de Lucas
Hospital Universitario 12 de Octubre, Madrid
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Isabel Perez Martinez, M. Eugenia Lauret, Andrés Castaño García,
Esmeralda Rubio
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Switzerland Alex Straumann Praxis für Gastroenterologie, Olten
Petr Hruz, Simon Brunner University Hospital Basel, Basel
United Kingdom Jamal Hayat, Andrew Poullis St. George’s Hospital, London
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Supplementary Figure 1. Study scheme. BID, twice daily; EOS-2, phase 3 maintenance study (EudraCT number 2014-
001485-99) offered to be entered by patients achieving clinico-histologic remission either at the end of the 6-wk DB or 6-wk
open-label induction phase.
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Supplementary Figure 2. CONSORT (Consolidated Standards of Reporting Trials) diagram showing the patient ﬂow in the
study. BID, twice daily; DB, 6-wk double-blind treatment phase; EOS-2, phase 3 maintenance study (EudraCT number 2014-
001485-99) offered to be entered by patients achieving clinico-histologic remission either at the end of the DB or OLI phase.
ITT, intention-to-treat; OLI, 6-wk open-label induction phase; PP, per-protocol.
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Supplementary Figure 3. Course of clinical remission in EoE
patients treated with BOTs for only 6 wk or in patients who
required a 12-wk treatment course. BID, twice daily.
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Supplementary Table 1.Study End Points
DB phase
Primary efﬁcacy variable
Rate of patients with clinico-histologic remission at wk 6 (LOCF), ie, achieving both, histologic remission (peak eosinophil count <16 eos/
mm2 hpf; equivalent to <5 eos/hpf) at wk 6 (LOCF), and clinical remission (symptoms severity of 2 points on 0–10 NRS for dysphagia
and a severity of 2 points on 0–10 NRS for odynophagia on each day in the week before wk 6 (LOCF). Patients who experienced a
food impaction needing endoscopic intervention, who needed a dilation during the study, or withdrew prematurely were assessed as
treatment failures
Note: 0–10 NRS range: 0 ¼ no symptoms, 10 ¼ most severe symptoms; hpf area of 0.345 mm2
A priori–ordered major secondary efﬁcacy end points
1. Rate of patients with histologic remission (as deﬁned in the primary end point) at wk 6 (LOCF),
2. Change in the peak eos/mm2 hpf from baseline to wk 6 (LOCF)
Note: hpf area of 0.345 mm2
3. Rate of patients with clinical remission (as deﬁned in the primary end point) on each day in the week before wk 6 (LOCF)
4. Rate of patients in remission (total weekly EEsAI-PRO 20) at wk 6 (LOCF)
Note: score range 0–100: 0 ¼ no EoE activity, 100 ¼ most severe EoE activity
Further secondary efﬁcacy variables
Clinical
Weekly sum of daily 0–10 NRS Dysphagia (range: 0–70)
Note: 0: no symptoms, 10: most severe symptoms
PGA of EoE Activity (NRS 0–10)
Note: score range 0–10: 0: no EoE activity, 10: most severe EoE activity
PatGA of EoE Activity (NRS 0–10)
Note: score range 0–10: 0: no EoE activity, 10: most severe EoE activity
Rate of patients with overall symptoms resolution deﬁned as PatGA 2 at wk 6 (LOCF)
Note: score range 0–10: 0: no EoE activity, 10: most severe EoE activity
Change from baseline to wk 6 (LOCF) in blood eosinophil counts (eos/mm3)
Endoscopy
Change from baseline to wk 6 (LOCF) in total modiﬁed EREFS endoscopic score
Note: score range 0–9: 0: no endoscopic EoE activity, 9: most severe endoscopic EoE activity
Change from baseline to wk 6 (LOCF) in modiﬁed EREFS inﬂammatory signs subscore (0–4)
Note: score range 0–4: 0: no inﬂammatory signs, 4: most severe inﬂammatory signs
Change from baseline to wk 6 (LOCF) in modiﬁed EREFS ﬁbrotic signs subscore (0–4)
Note: score range 0–4: 0: no ﬁbrotic signs, 4: most severe ﬁbrotic signs
Rate of patients with global assessment of endoscopic EoE activity of no signs of EoE at wk 6 (LOCF)
Histology
Rate of patients with histologic remission (i.e., peak eos <48 /mm2 hpf; equivalent to <15 eos/hpf) at wk 6 (LOCF), n (%)
HRQoL
Change from baseline to EoT DB phase in modiﬁed SHS Symptom Burden
Note: VAS 0–100; with lower values indicating better quality of life
Change from baseline to EoT DB phase in modiﬁed SHS Social Function
Note: VAS 0–100; with lower values indicating better quality of life
Change from baseline to EoT DB phase in modiﬁed SHS Disease–Related Worry
Note: VAS 0–100; with lower values indicating better quality of life
Change from baseline to EoT DB phase in modiﬁed SHS General Well-Being
Note: VAS 0–100; with lower values indicating better quality of life
Change from baseline to EoT DB phase in EoE-QoL-A 30 items (weighted average)
Note: 0 (very good HRQoL) to 4 (very poor HRQoL)
Change from baseline to EoT DB phase in EoE-QoL-A 24 items (weighted average)
Note: 0 (very good HRQoL) to 4 (very poor HRQoL)
Change from baseline to EoT DB phase in EoE-QoL-A eating/diet impact 10 items (weighted average)
Note: 0 (very good HRQoL) to 4 (very poor HRQoL)
Change from baseline to EoT DB phase in EoE-QoL-A eating/diet impact 4 items (weighted average)
Note: 0 (very good HRQoL) to 4 (very poor HRQoL)
Change from baseline to EoT DB phase in EoE-QoL-A social impact (weighted average)(weighted average)
Note: 0 (very good HRQoL) to 4 (very poor HRQoL)
Change from baseline to EoT DB phase in EoE-QoL-A emotional impact (weighted average)
Note: 0 (very good HRQoL) to 4 (very poor HRQoL)
Change from baseline to EoT DB phase in EoE-QoL-A disease anxiety (weighted average)
Note: 0 (very good HRQoL) to 4 (very poor HRQoL)
Change from baseline to EoT DB phase in EoE-QoL-A swallowing anxiety (weighted average)
Note: 0 (very good HRQoL) to 4 (very poor HRQoL)
Post-hoc analyses
Rate of patients in deep histologic remission at wk 6 deﬁned as peak eos/mm2 hpf of 0 in all biopsies
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DB phase
Safety variables
Adverse events
Vital signs (blood pressure, heart rate) and body weight
Standard hematology, blood chemistry, urinalysis
Morning serum cortisol
Assessment of tolerability by investigator and patient
Open-label induction phase
Further secondary efﬁcacy variables
Clinical
Rate of patients with clinico-histologic remission (as deﬁned in the primary end point) at EoT OLI phase
Note: for deﬁnitions see DB primary end point
Rate of patients with clinical remission (as deﬁned in the primary end point) at EoT OLI phase
Note: for deﬁnitions see DB primary end point
Rate of patients in remission (total weekly EEsAI-PRO 20) at EoT OLI phase
Change from EoT DB phase to EoT OLI phase in EEsAI-PRO
Rate of patients with no or only minimal problems deﬁned as 0–10 NRS dysphagia 2 on each day in the week before EoT OLI phase
Change from EoT DB phase to EoT OLI phase in weekly sum of daily 0–10 NRS dysphagia (range, 0–70)
Change from EoT DB phase to EoT OLI phase in PGA of EoE Activity (NRS 0–10)
Change from EoT DB phase to EoT OLI phase in PatGA of EoE Activity (NRS 0–10)
Change from EoT DB phase to EoT OLI phase in blood eosinophil counts (eos/mm3)
Endoscopy
Change from EoT DB phase to EoT OLI phase in total modiﬁed EREFS endoscopic score (0–9)
Change from EoT DB phase to EoT OLI phase in modiﬁed EREFS inﬂammatory signs subscore (0–4)
Change from EoT DB phase to EoT OLI phase in modiﬁed EREFS ﬁbrotic signs subscore (0–4)
Rate of patients with global assessment of endoscopic EoE activity of no signs of EoE at wk6
Histology
Rate of patients with histologic remission (as deﬁned in the primary end point) at EoT OLI phase
Rate of patients with histologic remission (ie, peak eos <48 /mm2 hpf; equivalent to <15 eos/hpf) at EoT OLI phase
Change from EoT DB phase to EoT OLI phase in overall peak eos/mm2 hpf
Note: hpf area of 0.345 mm2
HRQoL
Change from EoT DB phase to EoT OLI phase in modiﬁed SHS Symptom Burden
Note: VAS 0–100; with lower values indicating better quality of life
Change from EoT DB phase to EoT OLI phase in modiﬁed SHS Social Function
Note: VAS 0–100; with lower values indicating better quality of life
Change from EoT DB phase to EoT OLI phase in modiﬁed SHS Disease–Related Worry
Note: VAS 0–100; with lower values indicating better quality of life
Change from EoT DB phase to EoT OLI phase in modiﬁed SHS General Well–Being
Note: VAS 0–100; with lower values indicating better quality of life
Change from EoT DB phase to EoT OLI phase in EoE-QoL-A 30 items (weighted average)
Note: 0 (very good HRQoL) to 4 (very poor HRQoL)
Change from EoT DB phase to EoT OLI phase in EoE-QoL-A 24 items (weighted average)
Note: 0 (very good HRQoL) to 4 (very poor HRQoL)
Change from EoT DB phase to EoT OLI phase in EoE-QoL-A eating/diet impact 10 items (weighted average)
Note: 0 (very good HRQoL) to 4 (very poor HRQoL)
Change from EoT DB phase to EoT OLI phase in EoE-QoL-A eating/diet impact 4 items (weighted average)
Note: 0 (very good HRQoL) to 4 (very poor HRQoL)
Change from EoT DB phase to EoT OLI phase in EoE-QoL-A social impact (weighted average)
Note: 0 (very good HRQoL) to 4 (very poor HRQoL)
Change from EoT DB phase to EoT OLI phase in EoE-QoL-A emotional impact (weighted average)
Note: 0 (very good HRQoL) to 4 (very poor HRQoL)
Change from EoT DB phase to EoT OLI phase in EoE-QoL-A disease anxiety (weighted average)
Note: 0 (very good HRQoL) to 4 (very poor HRQoL)
Change from EoT DB phase to EoT OLI phase in EoE-QoL-A swallowing anxiety (weighted average)
Note: 0 (very good HRQoL) to 4 (very poor HRQoL)
Safety variables
Adverse events
Vital signs (blood pressure, heart rate) and body weight
Standard hematology, blood chemistry, urinalysis
Morning serum cortisol
Assessment of tolerability by investigator and patient
bid, twice daily; CI, conﬁdence interval; DB, double-blind; eos/hpf, eosinophils per high power ﬁeld (400); EoT, end of
treatment (wk 6 [LOCF]); LOCF, last observation carried forward.
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Supplementary Table 2.Protocol Prespeciﬁed Subgroup Analyses of the Primary Study End Point in Eosinophilic Esophagitis
Patients Treated With Budesonide Orodispersible Tablets or Placebo in the Double-Blind Phase
Characteristic
Patients in clinico-pathologic remission
at wk 6 (LOCF) stratiﬁed by protocol prespeciﬁed criteria
BOT 1 mg bid, n (%)
(n ¼ 59)
Placebo, n (%)
(n ¼ 29)
Localization of inﬂammation at baseline
Proximal esophagus
No 5/12 (41.7) 0/4 (0.0)
Yes 29/47 (61.7) 0/25 (0.0)
Middle esophagus
No 4/7 (57.1) 0/3 (0.0)
Yes 30/52 (57.7) 0/26 (0.0)
Distal esophagus
No 1/3 (33.3) 0/1 (0.0)
Yes 33/56 (58.9) 0/28 (0.0)
Extent of inﬂammation at baseline, no. of
esophageal segments affected
1 3/6 (50.0) 0/2 (0.0)
2 4/10 (40.0) 0/4 (0.0)
3 27/43 (62.8) 0/23 (0.0)
Peak eosinophil count/mm2 hpf at baseline
<Median 15/28 (53.6) 0/15 (0.0)
Median 19/31 (61.3) 0/14 (0.0)
Blood eosinophil count at baseline
Not evaluable 0/2 (0.0) 0/0 (0.0)
<Median 15/27 (55.6) 0/12 (0.0)
Median 19/30 (63.3) 0/17 (0.0)
Concomitant use of PPIs during the DB phase
No 29/52 (55.8) 0/26 (0.0)
Yes 5/7 (71.4) 0/3 (0.0)
History of allergic diseases
No 8/12 (66.7) 0/6 (0.0)
Yes 26/47 (55.3) 0/23 (0.0)
PatGA at baseline
3 or 4 9/12 (75.0) 0/5 (0.0)
5 11/16 (68.8) 0/7 (0.0)
6 5/8 (62.5) 0/5 (0.0)
7 4/13 (30.8) 0/8 (0.0)
8 or 9 5/10 (50.0) 0/4 (0.0)
Time since ﬁrst symptoms (disease duration)
Not evaluable 0/1 (0.0) 0/0 (0.0)
<Median 18/28 (64.3) 0/15 (0.0)
Median 16/30 (53.3) 0/14 (0.0)
History of any dietary approach to treat EoE
No 22/31 (71.0) 0/17 (0.0)
Yes 12/28 (42.9) 0/12 (0.0)
bid, twice daily; LOCF, last observation carried forward; PPI, proton-pump inhibitor.
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Supplementary Table 3.Exploratory Secondary Clinical, Histologic and Endoscopic Efﬁcacy End Points of Eosinophilic
Esophagitis Patients Treated With Budesonide Orodispersible Tablets 1 mg Twice Daily in the
Optional 6-Weeks Open-Label Phase
End Points
BOT/BOTa
(n ¼ 23)
Placebo/BOTb
(n ¼ 28)
General
Rate of patients with clinico-histologic remission (as
deﬁned in the primary end point) at EoT OLI phase, n (%)
16 (69.6) 22 (78.6)
Histology
Rate of patients with histologic remission (ie, peak eos
<16/mm2 hpf; equivalent to <5 eos/hpf) at EoT OLI
phase, n (%)
19 (82.6) 25 (89.3)
Rate of patients with histologic remission (ie, peak eos
<48/mm2 hpf; equivalent to <15 eos/hpf) at EoT OLI
phase, n (%)
20 (87.0) 25 (89.3)
Overall peak eos/mm2 hpf
EoT DB phase, mean (SD) 42 (107.2) 224 (94.5)
EoT OLI phase, mean (SD) 18 (56.7) 30 (80.7)
Change from EoT DB phase to EoT OLI phase, mean
(95% CI)
–12 (–39 to 15) –206 (–247 to –165)c
Clinic
Rate of patients with clinical remission (as deﬁned in the
primary end point) at EoT OLI phase, n (%)
17 (73.9) 23 (82.1)
Rate of patients in remission (total weekly EEsAI-PRO20) at:
EoT DB phase, n (%) 3 (13.0) 2 (7.1)
EoT OLI phase, n (%) 11 (47.8) 17 (60.7)
Total weekly EEsAI-PRO at:
EoT DB phase, mean (SD) 50.1 (21.8) 42.7 (16.3)
EoT OLI phase, mean (SD) 28.9 (26.0) 19.1 (19.1)
Change from EoT DB phase to EoT OLI phase, mean
(95% CI)
–21.2 (–31.5 to –10.9)c –23.6 (–30.4 to –16.9)c
Rate of patients with no or only minimal problems deﬁned
as 0–10 NRS dysphagia 2 on each day in the week
before:
EoT DB phase, n (%) 2 (8.7) 4 (14.3)
EoT OLI phase, n (%) 17 (73.9) 23 (82.1)
Weekly sum of daily 0–10 NRS dysphagia (range, 0–70) at:
EoT DB phase, mean (SD) 29.4 (16.7) 24.6 (11.1)
EoT OLI phase, mean (SD) 12.5 (12.0) 8.4 (10.6)
Change from EoT DB phase to EoT OLI phase, mean
(95% CI)
–16.8 (–23.0 to –10.6)c –16.1 (–20.7 to –11.6)c
PGA of EoE Activity (NRS 0–10) at:
EoT DB phase, mean (SD) 4.5 (2.5) 5.4 (2.1)
EoT OLI phase, mean (SD) 1.3 (1.5) 1.3 (1.3)
Change from EoT DB phase to EoT OLI phase, mean
(95% CI)
–3.3 (–4.5 to –2.2)c –4.1 (–5.0 to –3.2)c
PatGA of EoE Activity (NRS 0–10) at:
EoT DB phase, mean (SD) 4.8 (2.5) 4.0 (2.1)
EoT OLI phase, mean (SD) 1.9 (1.9) 1.4 (1.5)
Change from EoT DB phase to EoT OLI phase, mean
(95% CI)
–2.9 (–4.0 to –1.7)c –2.7 (–3.6 to –1.8)c
Blood eosinophil counts , eos/mm3
EoT DB phase, mean (SD) 193 (159) 412 (212)
EoT OLI phase, mean (SD) 201 (208) 208 (155)
Change from EoT DB phase to EoT OLI phase, mean
(95% CI)
–5 (–99 to 89) –211 (–287 to –135)c
Endoscopy
Total modiﬁed EREFS endoscopic score (0–9):
EoT DB phase, mean (SD) 2.1 (1.6) 4.5 (1.6)
EoT OLI phase, mean (SD) 1.0 (1.2) 1.1 (1.3)
Change from EoT DB phase to EoT OLI phase, mean
(95% CI)
–1.3 (–1.9 to –0.7)c –3.4 (–4.2 to –2.6)c
86.e8 Lucendo et al Gastroenterology Vol. 157, No. 1
Supplementary Table 4.Course and Absolute Changes from Baseline to Week 6 (Last Observation Carried Forward) of Peak
Eosinophilic Count/mm2 hpf (Total and by Esophageal Segment) in Eosinophilic Esophagitis Patients
Treated With Budesonide Orodispersible Tablets or Placebo in the Double-Blind Phase
Peak eosinophil
count per mm2 hpf
BOT 1 mg bid
(n ¼ 59)
Placebo
(n ¼ 29)
BOT–placebo,
mean difference
(95% CI)
Total
Baseline, mean (SD), n 242 (141), 59 239 (125), 29 —
EoT, mean (SD), n 16 (69), 59 224 (95), 28 —
Mean (95% CI) change
from baseline to EoT
–226 (–265 to –186) –4 (–56 to 47) –221 (–287 to –156)
P value <.0001a .7988a <.0001b
Proximal esophagus
Baseline, mean (SD), n 125 (138), 59 185 (143), 29 —
EoT, mean (SD), n 5 (26), 59 137 (107), 28 —
Mean (95% CI) change
from baseline to EoT
–120 (–157 to –83) –38 (–98 to 21) –82 (–148 to –15)
P value <.0001a .2463a .0171b
Mid esophagus
Baseline, mean (SD), n 148 (117), 59 178 (141), 29 —
EoT, mean (SD), n 10 (49), 59 168 (97), 28 —
Mean (95% CI) change
from baseline to EoT
–138 (–171 to –105) 1 (–61 to 63) –139 (–202 to –77)
P value <.0001a .9470a <.0001b
Distal esophagus
Baseline, mean (SD), n 200 (145), 59 159 (120), 29 —
EoT, mean (SD), n 16 (69), 59 182 (105), 28 —
Mean (95% CI) change
from baseline to EoT
–184 (–223 to –145) 36 (–19 to 91) –219 (–286 to –153)
P value <.0001a .1800a <.0001b
bid, twice daily; CI, conﬁdence interval; EoT, end of treatment (wk 6, last observation carried forward).
aWilcoxon signed rank test (2-sided, test within group).
bWilcoxon rank sum test (2-sided, test between groups).
Supplementary Table 3.Continued
End Points
BOT/BOTa
(n ¼ 23)
Placebo/BOTb
(n ¼ 28)
Modiﬁed EREFS inﬂammatory signs subscore (0–4):
EoT DB phase, mean (SD) 1.1 (1.1) 3.0 (1.0)
EoT OLI phase, mean (SD) 0.5 (0.9) 0.5 (0.8)
Change from EoT DB phase to EoT OLI phase, mean
(95% CI)
–0.6 (–1.2 to –0.1)c –2.4 (–3.0 to –1.9)c
Modiﬁed EREFS ﬁbrotic signs subscore (0–4):
EoT DB phase, mean (SD) 0.8 (0.8) 1.4 (1.0)
EoT OLI phase, mean (SD) 0.3 (0.6) 0.6 (0.6)
Change from EoT DB phase to EoT OLI phase, mean
(95% CI)
–0.5 (–0.9 to –0.2)c –0.9 (–1.2 to –0.5)c
Rate of patients with global assessment of endoscopic EoE
activity of “no signs of EoE”:
n ¼ 23 n ¼ 28
EoT DB phase, n (%) 11 (47.8) 0 (0)
EoT OLI phase, n (%) 15 (65.2) 17 (60.7)
bid, twice daily; CI, conﬁdence interval; EoT, end of treatment (wk 6 [last observation carried forward]).
aBOT/BOT: Patients who received BOT 1 mg bid and who were not in clinico-histologic remission at the end of the 6-wk DB
phase continued with a 6-wk open-label treatment with BOT 1 mg bid.
bPlacebo/BOT: Patients who received placebo and who were not in clinico-histologic remission at the end of the 6-wk DB
phase continued with a 6-wk open-label treatment with BOT 1 mg bid.
cSigniﬁcant changes from EoT DB phase to EoT OLI, as 0 was excluded from the 95% CI.
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Supplementary Table 5.Course and Absolute Changes From Baseline to Week 6 (Last Observation Carried Forward) of
Individual Subscores of the Modiﬁed Endoscopic Reference Score in Eosinophilic Esophagitis
Patients Treated With Budesonide Orodispersible Tablets or Placebo in the Double-Blind Phase
EREFS subscores
BOT 1 mg bid
(n ¼ 59)
Placebo
(n ¼ 29)
BOT-placebo,
mean difference
(95% CI)
Edema (range, 0–1)
Baseline, mean (SD) 0.7 (0.44), n ¼ 59 0.8 (0.38), n ¼ 29 —
EoT, mean (SD) 0.2 (0.36), n ¼ 59 0.8 (0.42), n ¼ 28 —
Change from baseline to EoT,
mean (95% CI)
–0.6 (–0.73 to –0.46) 0.0 (–0.20 to 0.13) –0.6 (–0.79 to –0.33)
P value <.0001 1.0000 <.0001
Exudates (range, 0–2)
Baseline, mean (SD) 1.1 (0.69), n ¼ 59 1.2 (0.77), n ¼ 29 —
EoT, mean (SD) 0.2 (0.46), n ¼ 59 1.2 (0.72), n ¼ 28 —
Change from baseline to EoT,
mean (95% CI)
–0.8 (–1.06 to –0.64) 0.0 (–0.28 to 0.28) –0.8 (–1.20 to –0.49)
P value <.0001 1.0000 <.0001
Furrows (range, 0–1)
Baseline, mean (SD) 0.8 (0.36), n ¼ 59 1.0 (0.00), n ¼ 29 —
EoT, mean (SD) 0.2 (0.41), n ¼ 58 1.0 (0.00), n ¼ 28 —
Change from baseline to EoT,
mean (95% CI)
–0.6 (–0.77 to –0.50) 0.0 (—) –0.6 (–0.83 to –0.44)
P value <.0001 — <.0001
Fixed rings (range, 0–3)
Baseline, mean (SD) 0.8 (0.84), n ¼ 59 1.3 (0.76), n ¼ 29 —
EoT, mean (SD) 0.5 (0.68), n ¼ 59 1.3 (0.80), n ¼ 28 —
Change from baseline to EoT,
mean (95% CI)
–0.3 (–0.52 to –0.09) –0.1 (–0.45 to 0.23) –0.2 (–0.59 to 0.19)
P value .0061 .6509 .3851
Stricture (range, 0–1)
Baseline, mean (SD) 0.2 (0.36), n ¼ 59 0.1 (0.35), n ¼ 29 —
EoT, mean (SD) 0.1 (0.22), n ¼ 59 0.2 (0.39), n ¼ 28 —
Change from baseline to EoT,
mean (95% CI)
–0.1 (–0.18 to –0.02) 0.0 (–0.16 to 0.23) –0.1 (–0.31 to 0.04)
P value P.0313 1.0000 .1384
Crêpe paper esophagus (range, 0–1)
Baseline, mean (SD) 0.2 (0.38), n ¼ 59 0.1 (0.31), n ¼ 29 —
EoT, mean (SD) 0.1 (0.25), n ¼ 59 0.1 (0.31), n ¼ 28 —
Change from baseline to EoT,
mean (95% CI)
–0.1 (–0.19 to –0.01) 0.0 (–0.15 to 0.15) –0.1 (–0.27 to 0.07)
P value .0703 1.0000 .2394
NOTE. All intra-group comparisons were performed using exploratory 2-sided Wilcoxon signed-rank test. All intergroup
comparisons were performed using exploratory 2-sided Wilcoxon rank sum test.
bid, twice daily; CI, conﬁdence interval; EoT, end of treatment (wk 6 [last observation carried forward]).
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Supplementary Table 6.Course and Absolute Changes From Baseline to Week 6 (Last Observation Carried Forward) of the
Total Eosinophilic Esophagitis Quality of Life Scale for Adults Questionnaire and its Subscores in
Eosinophilic Esophagitis Patients Treated With Budesonide Orodispersible Tablets or Placebo in the
Double-Blind Phase
Scores range: 0–4, with higher scores denote
better HRQoL
BOT 1 mg bid
(n ¼ 59)
Placebo
(n ¼ 29)
BOT–placebo,
mean difference
(95% CI)
EoE-QoL-A 30-items (weighted average)
Baseline, mean (SD) 2.3 (0.8) 2.3 (0.8) —
EoT, mean (SD) 2.8 (0.9) 2.6 (0.7) —
Change from baseline to EoT, mean (95% CI) 0.5 (0.32 to 0.62) 0.2 (0.06 to 0.42) 0.23 (–0.010 to 0.472)
P value <.0001 .0115 .0602
EoE-QoL-A 24 items (weighted average)
Baseline, mean (SD) 2.2 (0.8) 2.3 (0.8) —
EoT, mean (SD) 2.7 (0.9) 2.6 (0.7) —
Change from baseline to EoT, mean (95% CI) 0.5 (0.33 to 0.63) 0.2 (0.07 to 0.42) 0.24 (–0.004 to 0.476)
P value <.0001 .0093 .0534
EoE-QoL-A eating/diet impact 10 items (weighted
average)
Baseline, mean (SD) 2.2 (1.0) 2.3 (0.8) —
EoT, mean (SD) 2.9 (1.0) 2.5 (0.7) —
Change from baseline to EoT, mean (95% CI) 0.7 (0.41 to 0.88) 0.2 (–0.08 to 0.38) 0.50 (0.174 to 0.817)
P value <.0001 P ¼ .1848 P ¼ .0030
EoE-QoL-A eating/diet impact 4 items, (weighted
average)
Baseline, mean (SD) 2.1 (1.0) 2.2 (0.9) —
EoT, mean (SD) 2.8 (1.0) 2.4 (0.8) —
Change from baseline to EoT, mean (95% CI) 0.7 (0.46 to 0.92) 0.2 (–0.04 to 0.44) 0.49 (0.131 to 0.858)
P value <.0001 .1039 .0082
EoE-QoL-A social impact (weighted average)
Baseline, mean (SD) 2.1 (1.0) 2.2 (1.0) —
EoT, mean (SD) 2.6 (1.1) 2.5 (0.9) —
Change from baseline to EoT, mean (95% CI) 0.5 (0.27 to 0.65) 0.3 (0.02 to 0.58) 0.16 (–0.172 to 0.490)
P value <.0001 .0364 .3430
EoE-QoL-A emotional impact (weighted average)
Baseline, mean (SD) 2.6 (0.9) 2.7 (0.8) —
EoT, mean (SD) 3.0 (0.9) 2.9 (0.7) —
Change from baseline to EoT, mean (95% CI) 0.4 (0.28 to 0.60) 0.2 (0.04 to 0.43) 0.20 (–0.055 to 0.459)
P value <.0001 .0186 .1216
EoE-QoL-A disease anxiety (weighted average)
Baseline, mean (SD) 2.0 (0.9) 1.8 (0.9) —
EoT, mean (SD) 2.3 (1.0) 2.0 (0.9) —
Change from baseline to EoT, mean (95% CI) 0.3 (0.17 to 0.45) 0.2 (–0.04 to 0.34) 0.16 (–0.077 to 0.395)
P value <.0001 .1078 .1840
EoE-QoL-A swallowing anxiety (weighted average)
Baseline, mean (SD) 2.1 (1.0) 2.3 (1.1) —
EoT, mean (SD) 2.7 (1.1) 2.8 (0.9) —
Change from baseline to EoT, mean (95% CI) 0.6 (0.39 to 0.80) 0.4 (0.13 to 0.68) 0.19 (–0.150 to 0.539)
P value <.0001 .0055 .2656
NOTE. All intra- and inter-group comparisons were performed using 2-sided, 2-sample t test and 2-sided t test, respectively.
bid, twice daily; CI, conﬁdence interval; EoT, end of treatment (wk 6 [last observation carried forward]).
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Supplementary Table 7.Exploratory Quality of Life End Points of Eosinophilic Esophagitis Patients Treated With Budesonide
Orodispersible Tablets 1 mg Twice Daily in the Optional 6-Weeks Open-Label Phase
End points
BOT/BOTa
(n ¼ 23)
Placebo/BOTb
(n ¼ 29)
Modiﬁed SHS (scores range, 0–100, with lower scores denote better
HRQoL)
Modiﬁed SHS Symptom Burden:
EoT DB phase, mean (SD) 51 (23.8) 37 (25.5)
EoT OLI phase, mean (SD) 23 (23.6) 14 (16.2)
Change from EoT DB phase to EoT OLI phase, mean (95% CI) –28 (–40.7 to –14.8)c –24 (–32.6 to –14.5)c
Modiﬁed SHS Social Function:
EoT DB phase, mean (SD) 51 (24.5) 33 (23.5)
EoT OLI phase, mean (SD) 26 (25.6) 15 (16.7)
Change from EoT DB phase to EoT OLI phase, mean (95% CI) –25 (–35.4 to –14.5)c –18 (–26.7 to –9.3)c
Modiﬁed SHS Disease-Related Worry:
EoT DB phase, mean (SD) 63 (21.2) 45 (28.6)
EoT OLI phase, mean (SD) 51 (23.7) 31 (24.4)
Change from EoT DB phase to EoT OLI phase, mean (95% CI) –12 (–20.2 to –3.9) c –14 (–22.9 to –5.0) c
Modiﬁed SHS General Well-Being:
EoT DB phase, mean (SD) 45 (22.6) 27 (24.2)
EoT OLI phase, mean (SD) 27 (23.2) 14 (15.2)
Change from EoT DB phase to EoT OLI phase, mean (95% CI) –18 (–26.9 to –8.4)c –13 (–21.6 to –4.3)c
EoE-QoL-A (Scores range 0–4, with higher scores denote better HRQoL)
EoE-QoL-A 30-items (weighted average)
EoT DB phase, mean (SD) 2.0 (0.8) 2.5 (0.7)
EoT OLI phase, mean (SD) 2.2 (0.7) 2.8 (0.6)
Change from EoT DB phase to EoT OLI phase, mean (95% CI) 0.16 (0.003 to 0.327)c 0.29 (0.072 to 0.512)c
EoE-QoL-A 24-items (weighted average)
EoT DB phase, mean (SD) 2.0 (0.8) 2.5 (0.7)
EoT OLI phase, mean (SD) 2.5 (0.7) 2.8 (0.6)
Change from EoT DB phase to EoT OLI phase, mean (95% CI) 0.17 (0.017 to 0.324)c 0.28 (0.061 to 0.505)c
EoE-QoL-A eating/diet impact 10 items (weighted average)
EoT DB phase, mean (SD) 2.1 (0.9) 2.5 (0.8)
EoT OLI phase, mean (SD) 2.4 (1.0) 2.9 (0.7)
Change from EoT DB phase to EoT OLI phase, mean (95% CI) 0.33 (0.085 to 0.580)c 0.49 (0.217 to 0.754)c
EoE-QoL-A eating/diet impact 4 items (weighted average)
EoT DB phase, mean (SD) 2.0 (0.9) 2.4 (0.8)
EoT OLI phase, mean (SD) 2.4 (0.9) 2.9 (0.8)
Change from EoT DB phase to EoT OLI phase, mean (95% CI) 0.39 (0.157 to 0.626)c 0.46 (0.164 to 0.747)c
EoE-QoL-A social impact (weighted average)
EoT DB phase, mean (SD) 1.9 (1.2) 2.5 (0.9)
EoT OLI phase, mean (SD) 1.9 (1.1) 2.9 (0.8)
Change from EoT DB phase to EoT OLI phase, mean (95% CI) 0.04 (–0.212 to 0.299) 0.45 (0.073 to 0.820)c
EoE-QoL-A emotional impact (weighted average)
EoT DB phase, mean (SD) 2.3 (0.9) 2.9 (0.7)
EoT OLI phase, mean (SD) 2.5 (0.7) 3.1 (0.5)
Change from EoT DB phase to EoT OLI phase, mean (95% CI) 0.15 (–0.025 to 0.318) 0.22 (–0.004 to 0.436)
EoE-QoL-A disease anxiety (weighted average)
EoT DB phase, mean (SD) 1.5 (0.8) 2.0 (0.9)
EoT OLI phase, mean (SD) 1.7 (0.8) 2.1 (0.9)
Change from EoT DB phase to EoT OLI phase, mean (95% CI) 0.16 (–0.055 to 0.368) 0.16 (–0.080 to 0.397)
EoE-QoL-A swallowing anxiety (weighted average)
EoT DB phase, mean (SD) 1.9 (1.1) 2.7 (0.9)
EoT OLI phase, mean (SD) 2.0 (1.0) 2.9 (0.8)
Change from EoT DB phase to EoT OLI phase, mean (95% CI) 0.13 (–0.077 to 0.338) 0.20 (–0.029 to 0.434)
bid, twice daily; CI, conﬁdence interval; EoT, end of treatment (wk 6 [last observation carried forward]); HRQoL, Health-Related
Quality of Life.
aBOT/BOT: Patients who received BOT 1 mg bid and who were not in clinico-histologic remission at the end of the 6-wk DB
phase continued with a 6-wk open-label treatment with BOT 1 mg bid.
bPlacebo/BOT: Patients who received placebo and who were not in clinico-histologic remission at the end of the 6-wk DB
phase continued with a 6-wk open-label treatment with BOT 1 mg bid.
cSigniﬁcant changes from EoT DB phase to EoT OLI, as 0 was excluded from the 95% CI.
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Supplementary Table 8.Mean Serum Morning (8:00–09:00 AM) Cortisol Levels and Change from Baseline in Eosinophilic
Esophagitis Patients Treated with Budesonide Orodispersible Tablets or Placebo in the Double-Blind
Phase, the Optional 6-Week Open-Label Phase, and the Follow-Up Phase (if Not Switched to Study
EOS-2 after Double-Blind End of Treatment or Open-Label Induction/End of Treatment
Cortisol levels, mg/dL
BOT 1 mg bid
(n ¼ 59)
Placebo
(n ¼ 29)
BOT–placebo,
mean difference
(95% CI)
Baseline, mean (SD), n 12.6 (4.8), 52 12.5 (4.4), 27 —
EoT, mean (SD), n 11.9 (4.6), 54 11.2 (4.5), 27 —
Change from baseline to EoT,
mean (95% CI), n
–1.1 (–2.0 to –0.1), 52 –1.3 (–2.9 to 0.2), 27 0.3 (–1.4 to 1.9)
P value — — .7272
BOT/BOTa
(n ¼ 23)
Placebo/BOTb
(n ¼ 28)
BOT–placebo,
mean difference
(95% CI)
EoT DB phase, mean (SD), n 12.1 (4.5), 19 10.1 (3.3), 22 —
EoT OLI phase, mean (SD), n 12.4 (4.8), 20 10.11 (3.7), 26 —
Change from EoT DB phase
to EoT OLI phase,
mean (95% CI), n
0.04 (–1.9 to 2.0) , 19 0.5 (–0.9 to 1.9), 22 —
Follow-up Follow-up
EoT DB or OLI phase, mean (SD), n 11.9 (4.9), 18 14.8, 1 —
EoT FU phase, mean (SD), n 13.1 (5.6), 18 4.0, 1c —
Change from EoT DB or OLI phase
to EoT FU phase, mean (95% CI)
1.3 (–0.4 to 2.9), 18 –10.8, 1 —
bid, twice daily; CI, conﬁdence interval; EoT, end of treatment (wk 6, last observation carried forward); FU, follow-up.
aBOT/BOT: Patients who received BOT 1 mg bid and who were not in clinico-histologic remission at the end of the 6-wk DB
phase continued with a 6-wk open-label treatment with BOT 1 mg bid.
bPlacebo/BOT: Patients who received placebo and who were not in clinico-histologic remission at the end of the 6-wk DB
phase continued with a 6-wk open-label treatment with BOT 1 mg bid.
cThe patient experienced a food impaction during double-blind treatment phase requiring endoscopic emergency intervention
outside the study setting and was treated throughout the FU phase with budesonide asthma medication twice daily, which
explains the drop of serum morning cortisol from EoT to FU. The FU value was assessed by the investigator of being not
clinically relevant.
Supplementary Table 9.Serum Morning Cortisol Levels of Patients With Clinically Relevant Abnormal Values Below Lower
Limit of Normal (<6.2 mg/dL)
Variable Baseline DB EoT DB EoT OLI FU
BOT 1 mg bid
Patient 1 10.1 3.7 a — —
Patient 2 6.5 5.8 10.2c —
Patient 3 11.6 2.7 a,b — —
Placebo
Patient 1 8.2 15.8 2.2c —
bid, twice daily; EoT, end of treatment (wk 6, last observation carried forward); FU, follow-up.
aPatient switched over to EOS-2 maintenance trial after completion of DB phase. Therefore, no FU value is available.
bSample was taken outside the requested window of 08:00-09:00 a.m.
cPatient switched over to EOS-2 maintenance trial after completion of OLI phase. Therefore, no FU value is available.
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Supplementary Table 10.Eosinophilic Esophagitis Patients Treated With Budesonide Orodispersible Tablets 1 mg Twice
Daily in the Optional 6-Week Open-label Phase and Experiencing Treatment-Related Adverse
Events
Variable
BOT/BOT,a
n (%)
(n ¼ 23)
Placebo/BOT,b
n (%)
(n ¼ 28)
Any TEAE 13 (56.5) 16 (57.1)
Severe TEAE
Esophageal food impaction
TEAE related to study drug 6 (26.1) 13 (46.4)
Serious adverse events 0 (0) 0 (0)
TEAE leading to withdrawal from the study 0 (0) 1 (3.6)
Lip edema and oral paraesthesia, both of mild intensity and recovered 0 (0) 1 (3.6)
TEAE related to study drug and leading to withdrawal from the study 0 (0) 1 (3.6)
TEAEs by occurring in 2 patients in any treatment group:
Gastrointestinal disorders 3 (13.0) 2 (7.1)
Gastroesophageal reﬂux disease 2 (8.7) 1 (3.6)
Infections and infestations 4 (17.4) 12 (42.9)
Suspected local fungal infection,c thereof: 4 (17.4) 10 (35.7)
Histologically conﬁrmedd 2 (8.7) 7 (25.0)
Histologically conﬁrmedd with suspected endoscopic signs 1 (4.3) 6 (21.4)
Histologically conﬁrmedd with suspected endoscopic signs and clinical symptoms 0 (0) 0 (0)
Nervous system disorders 4 (17.4) 1 (3.6)
Headache 4 (17.4) 1 (3.6)
bid, twice daily; TEAE, treatment-emergent adverse events.
aBOT/BOT: Patients who received BOT 1 mg bid and who were not in clinico-histologic remission at the end of the 6-wk DB
phase continued with a 6-wk open-label treatment with BOT 1mg bid
bPlacebo/BOT: Patients who received placebo and who were not in clinico-histologic remission at the end of the 6-wk DB
phase continued with a 6-wk open-label treatment with BOT 1 mg bid.
cLocal fungal infection (included suspected cases of candida infection, esophageal candidiasis, oral candidiasis, and
oropharyngeal candidiasis) was suspected and assessed as an adverse event if any of the following criteria was fulﬁlled:
suspected clinical symptoms, suspected endoscopic ﬁndings, suspected histologic assessment in H&E-stained biopsies
(even without any endoscopic signs or clinical symptoms).
dHistologically conﬁrmed by Grocott staining.
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Supplementary Table 11.Efﬁcacy of Drug Interventions for
Treating Eosinophilic Esophagitis
in the Past (Previous Acute and/or
Maintenance Treatment)
Previously
reported
efﬁcacy
BOT 1 mg
bid, n (%)
(n ¼ 59)
Placebo,
n (%)
(n ¼ 29)
PPI 32 (54)a 13 (45)a
Poor 25/32 (78) 11/13 (85)
Satisfactory 2/32 (6) 1/13 (8)
Good 0/32 (0) 1/13 (8)
Very good 2/32 (6) 0/13 (0)
Unknown 3/32 (9) 0/13 (0)
Topical budesonide 12 (20) 3 (10)
Poor 0/12 (0) 0/3 (0)
Satisfactory 3/12 (25) 0/3 (0)
Good 6/12 (50) 2/3 (67)
Very good 3/12 (25) 1/3 (33)
Topical ﬂuticasone 25 (42) 14 (48)
Poor 7/25 (28) 3/14 (21)
Satisfactory 1/25 (4) 2/14 (14)
Good 11/25 (44) 7/14 (50)
Very good 5/25 (20) 1/14 (7)
Unknown 1/25 (4) 1/14 (7)
Systemic steroids 3 (5) 0 (0)
Good 1/3 (33) 0/0 (0)
Very good 1/3 (33) 0/0 (0)
Unknown 1/3 (33) 0/0 (0)
Montelukast 4 (7) 0 (0)
Good 1/4 (25) 0/0 (0)
Poor 2/4 (50) 0/0 (0)
Unknown 1/4 (25) 0/0 (0)
bid, twice daily; n, valid numbers; PPI, proton pump inhibitor.
aAll patients failed PPI trial (either in their history or during the
screening phase.
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